definiens: means all compounds contro lled by Infinity that wereidentified and provided to Amgen under the terms of the Amgen Agreement, prior to any renewals by Amge n. To the extentthat the supply of compounds from any given Synthet ic Pathway is insufficient to meet requirements her eunder, Infinity willuse commercially reasonable efforts to resynthesize compounds from such Synthetic Pathway ; provided, h owever, that ifInfinity is unable to supply compounds from any Syn thetic Pathway, Infinity will include in the Librar y Compound Poolcompounds from Synthetic Pathways not provided to A mgen under the terms of the Amgen Agreement, prior to any renewalsby Amgen, until Infinity has satisfied its obligati on to provide JJPRD Library Compounds from a minimu m of [ * * ] SyntheticPathways and a pool of [ * * ] compounds . Additionally, shall specifically includ e any compoundreferenced to JJPRD in a certain database to which Infinity has provided JJPRD access, any compound 4controlled by Infinity and made by Infinity by any one of synthetic pathways designated [ * * ] and [ * * ] prior to December 31,2005 and any compound Controlled by Infinity and ma de by Infinity by a diversity oriented chemistry sy nthetic pathwayprior to December 31, 2005 . Notwithstanding the for egoing, the Library Compound Pool will exclude any compound that(a ) if delivered would violate an obligation of Inf inity of confidentiality to a Third Party, ( b ) is g enerated by Infinity asfocused compound sets based on hits against a speci fic target, ( c ) was in Infinity ’s [ * * ] Hit - to - Lead Chemistry Programs inexistence as of 12/19/03, the effective date of the Amgen agreement, ( which include, in the aggregate no more than [ * * ] compounds ), or ( d ) Infinity has previously filed a patent application that specifically claims the com position of matter by aunique name or designation of the compound included in the Library Compound Pool prior to the date on which suchcompound was delivered to JJPRD